Sona Nanotech Inc (TSE:SONA) has released an update.
Sona Nanotech Inc. reports a breakthrough in its preclinical studies where its Targeted Hyperthermia Therapy, combined with immunotherapy, not only shrank primary tumors in mice but also eliminated untreated distant tumors, demonstrating a ‘vaccine effect’ with lasting immunity against cancer recurrence. The promising results, indicating potential for a novel cancer treatment, are propelling the company towards regulatory studies for human trials, targeting individuals with late-stage melanoma.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
